Cedars-Sinai Medical Center, Smidt Heart Institute, 127 S. San Vicente Blvd., Los Angeles, CA, 90048, USA.
Division of Cardiovascular Medicine, Department of Medicine, China Medical University and Hospital, Taichung, Taiwan.
Basic Res Cardiol. 2021 Jun 4;116(1):39. doi: 10.1007/s00395-021-00877-5.
Arrhythmogenic cardiomyopathy (AC) is an inherited disease characterized by progressive breakdown of heart muscle, myocardial tissue death, and fibrofatty replacement. In most cases of AC, the primary lesion occurs in one of the genes encoding desmosomal proteins, disruption of which increases membrane fragility at the intercalated disc. Disrupted, exposed desmosomal proteins also serve as epitopes that can trigger an autoimmune reaction. Damage to cell membranes and autoimmunity provoke myocardial inflammation, a key feature in early stages of the disease. In several preclinical models, targeting inflammation has been shown to blunt disease progression, but translation to the clinic has been sparse. Here we review current understanding of inflammatory pathways and how they interact with injured tissue and the immune system in AC. We further discuss the potential role of immunomodulatory therapies in AC.
致心律失常性右室心肌病(AC)是一种遗传性疾病,其特征为进行性心肌破坏、心肌组织死亡和纤维脂肪替代。在 AC 的大多数情况下,原发性病变发生在编码桥粒蛋白的基因之一中,桥粒蛋白的破坏会增加闰盘处的膜脆性。破坏的、暴露的桥粒蛋白也作为抗原决定簇,可以触发自身免疫反应。细胞膜损伤和自身免疫会引发心肌炎症,这是疾病早期的一个关键特征。在几个临床前模型中,靶向炎症已被证明可以减缓疾病进展,但在临床上应用却很少。在这里,我们回顾了炎症途径的现有认识,以及它们如何与 AC 中的受损组织和免疫系统相互作用。我们还进一步讨论了免疫调节疗法在 AC 中的潜在作用。